Related Experiment Video
Updated: May 21, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dabigatran for stroke prevention in atrial fibrillation
1J. W. Goethe University, Frankfurt am Main, Germany. Hohnloser@em.uni-frankfurt.de
Insights
Dabigatran offers effective stroke prevention for atrial fibrillation patients, showing similar efficacy to warfarin with less major bleeding. Specific dosages are recommended based on patient age to minimize bleeding risks.
Area of Science:
- Cardiology
- Pharmacology
- Neurology
Background:
- Atrial fibrillation increases stroke and embolism risk.
- Warfarin is a standard anticoagulant but has limitations.
- Novel anticoagulants are needed for improved stroke prevention.
Purpose of the Study:
- To evaluate the efficacy and safety of dabigatran etexilate compared to warfarin.
- To determine optimal dosing strategies for dabigatran in atrial fibrillation patients.
- To assess the impact of dabigatran on stroke, systemic embolism, and bleeding events.
Main Methods:
- The RE-LY study was a pivotal, randomized, controlled trial.
- Patients with atrial fibrillation received dabigatran (110 mg or 150 mg twice daily) or warfarin.
- Outcomes included stroke, systemic embolism, major hemorrhage, and myocardial infarction.
Main Results:
- Dabigatran 110 mg BID showed similar stroke prevention to warfarin with less major bleeding.
- Dabigatran 150 mg BID was more effective in stroke prevention than warfarin, with similar major bleeding rates.
- Both dabigatran doses significantly reduced hemorrhagic stroke risk by 60-70%.
- Higher dabigatran 150 mg BID dose associated with increased extracranial bleeding in patients ≥75-80 years.
- Myocardial infarction rates were low, with a numerical increase in dabigatran groups.
Conclusions:
- Dabigatran is a safe and effective alternative to warfarin for stroke prevention in atrial fibrillation.
- Dose selection of dabigatran (110 mg or 150 mg BID) should consider patient age and bleeding risk.
- Dabigatran provides significant reduction in hemorrhagic stroke and overall stroke risk.
Abstract:
Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation. In the pivotal RE-LY study, dabigatran 110 mg BID was demonstrated to be associated with a stroke rate similar to that observed with warfarin (INR target 2.0 to 3.0), but with a lower rate of major haemorrhage. Dabigatran administered at a dose of 150 mg BID was significantly more effective in stroke prevention than warfarin and showed a similar rate of major hemorrhages. Of note, both dosages resulted in an approximately 60-70% relative risk reduction of haemorrhagic stroke. The dosage of 110 mg BID should be preferably used in patients aged 75-80 years or older as the rate of extracranial bleeding events tends to increase with dabigatran 150 mg BID above this age limit. In RE-LY, myocardial infarcts occurred at a very low incidence. There were numerically more myocardial infarcts in dabigatran-treated patients than in warfarin patients; however, other myocardial ischaemic events were similar in the three treatment arms.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures